Literature DB >> 14693372

Detailed mapping of the ERG-ETS2 interval of human chromosome 21 and comparison with the region of conserved synteny on mouse chromosome 16.

C M Owczarek1, K J Portbury, M P Hardy, D A O'Leary, J Kudoh, K Shibuya, N Shimizu, I Kola, P J Hertzog.   

Abstract

We have carried out a detailed annotation of 550 kb of genomic DNA on human chromosome 21 containing the ERG and ETS2 genes. Comparative genomic analysis between this region and the interval of conserved synteny on mouse chromosome 16 indicated that the order and orientation of the ERG and ETS2 genes were conserved and revealed several regions containing potential conserved noncoding sequences. Four pseudogenes including those for small protein G, laminin receptor, human transposase protein and meningioma-expressed antigen were identified. A potentially novel gene (C21orf24) with alternative mRNA transcripts, consensus splice donor and acceptor sites, but no coding potential nor murine orthologue, was identified and found to be expressed in a range of human cell lines. We have identified four novel splice variants that arise from a previously undescribed 5' exon of the human ERG gene. Comparison of the cDNA sequences enabled us to determine the complete exon-intron structure of the ERG gene. We have also identified the presence of noncoding RNAs in the first and second introns of the ETS2 gene. Our studies have important implications for Down syndrome as this region contains multiple mRNA transcripts, both coding and potentially noncoding, that may play as yet undescribed roles in the pathogenesis of this disorder.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14693372     DOI: 10.1016/j.gene.2003.09.047

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  17 in total

1.  Copy number variations in 375 patients with oesophageal atresia and/or tracheoesophageal fistula.

Authors:  Erwin Brosens; Florian Marsch; Elisabeth M de Jong; Hitisha P Zaveri; Alina C Hilger; Vera Gisela Choinitzki; Alice Hölscher; Per Hoffmann; Stefan Herms; Thomas M Boemers; Benno M Ure; Martin Lacher; Michael Ludwig; Bert H Eussen; Robert M van der Helm; Hannie Douben; Diane Van Opstal; Rene M H Wijnen; H Berna Beverloo; Yolande van Bever; Alice S Brooks; Hanneke IJsselstijn; Daryl A Scott; Johannes Schumacher; Dick Tibboel; Heiko Reutter; Annelies de Klein
Journal:  Eur J Hum Genet       Date:  2016-07-20       Impact factor: 4.246

2.  Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements.

Authors:  Paula Paulo; Franclim R Ribeiro; Joana Santos; Diana Mesquita; Mafalda Almeida; João D Barros-Silva; Harri Itkonen; Rui Henrique; Carmen Jerónimo; Anita Sveen; Ian G Mills; Rolf I Skotheim; Ragnhild A Lothe; Manuel R Teixeira
Journal:  Neoplasia       Date:  2012-07       Impact factor: 5.715

Review 3.  ERG expression in prostate cancer: biological relevance and clinical implication.

Authors:  Hatem Abou-Ouf; Liena Zhao; Tarek A Bismar
Journal:  J Cancer Res Clin Oncol       Date:  2015-12-28       Impact factor: 4.553

4.  Aberrant expression of ETS1 and ETS2 proteins in cancer.

Authors:  Elizabeth A Fry; Kazushi Inoue
Journal:  Cancer Rep Rev       Date:  2018-04-23

Review 5.  The oncogene ERG: a key factor in prostate cancer.

Authors:  P Adamo; M R Ladomery
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

Review 6.  ETS gene fusions in prostate cancer.

Authors:  Jeremy P Clark; Colin S Cooper
Journal:  Nat Rev Urol       Date:  2009-08       Impact factor: 14.432

7.  TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation.

Authors:  C Sun; A Dobi; A Mohamed; H Li; R L Thangapazham; B Furusato; S Shaheduzzaman; S-H Tan; G Vaidyanathan; E Whitman; D J Hawksworth; Y Chen; M Nau; V Patel; M Vahey; J S Gutkind; T Sreenath; G Petrovics; I A Sesterhenn; D G McLeod; S Srivastava
Journal:  Oncogene       Date:  2008-06-09       Impact factor: 9.867

8.  TMPRSS2- driven ERG expression in vivo increases self-renewal and maintains expression in a castration resistant subpopulation.

Authors:  Orla M Casey; Lei Fang; Paul G Hynes; Wassim G Abou-Kheir; Philip L Martin; Heather S Tillman; Gyorgy Petrovics; Hibah O Awwad; Yvona Ward; Ross Lake; Luhua Zhang; Kathleen Kelly
Journal:  PLoS One       Date:  2012-07-30       Impact factor: 3.240

9.  Oncogenic activation of ERG: A predominant mechanism in prostate cancer.

Authors:  Taduru L Sreenath; Albert Dobi; Gyorgy Petrovics; Shiv Srivastava
Journal:  J Carcinog       Date:  2011-12-31

10.  5' UTR control of native ERG and of Tmprss2:ERG variants activity in prostate cancer.

Authors:  Francesca Zammarchi; George Boutsalis; Luca Cartegni
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.